PMC:7454258 / 29029-29415 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T93788","span":{"begin":86,"end":91},"obj":"Body_part"},{"id":"T49806","span":{"begin":263,"end":267},"obj":"Body_part"}],"attributes":[{"id":"A60884","pred":"fma_id","subj":"T93788","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A84536","pred":"fma_id","subj":"T49806","obj":"http://purl.org/sig/ont/fma/fma256135"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T7","span":{"begin":86,"end":91},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T68","span":{"begin":278,"end":286},"obj":"Disease"}],"attributes":[{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T13896","span":{"begin":86,"end":91},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T65382","span":{"begin":86,"end":91},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T88718","span":{"begin":324,"end":327},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T65768","span":{"begin":349,"end":352},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T33","span":{"begin":50,"end":56},"obj":"Chemical"},{"id":"T34","span":{"begin":175,"end":184},"obj":"Chemical"},{"id":"T35","span":{"begin":248,"end":258},"obj":"Chemical"}],"attributes":[{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_26708"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_26216"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_50505"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}

{"project":"LitCovid-PubTator","denotations":[{"id":"176","span":{"begin":50,"end":56},"obj":"Chemical"},{"id":"177","span":{"begin":175,"end":184},"obj":"Chemical"},{"id":"193","span":{"begin":278,"end":286},"obj":"Disease"}],"attributes":[{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"MESH:D012964"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"MESH:D011188"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:D003920"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}

{"project":"LitCovid-sentences","denotations":[{"id":"T185","span":{"begin":0,"end":386},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk."}